
Data on the use of biologic therapy and malignancy risk are inconsistent due to limited long‐term robust studies. To assess the malignancy risk in patients with secukinumab‐treated psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). This integrated safety analysis from both the secukinumab clinical trial programme and postmarketing safety surveillance data included any patient receiving at least one approved dose of secukinumab with a maximum of 5 years of follow‐up...
Like
Save
Share